EuroBiotech: More Articles of Note


> Vicore Pharma struck a deal to buy INIM Pharma. The takeover will give Vicore control of an experimental inhaled immunomodulatory treatment for idiopathic pulmonary fibrosis and other lung diseases. Release   

> iTeos Therapeutics named Scott Chappel, Ph.D., as its CSO. Chappel was a founder and chief technology officer at Surface Oncology. Statement 

> A phase 2b trial of Neovacs’ IFNalpha Kinoid in lupus missed its primary efficacy endpoint. But with other measures painting the drug in a better light, Neovacs still plans to move into phase 3. Release 


Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> VarmX raised €12.5 million ($14.6 million) to move its treatment for severe bleeding in patients taking anticoagulants into human testing. Statement

> Sanofi’s Ablynx took a big step toward the European approval of Cablivi, its treatment for acquired thrombotic thrombocytopenic purpura. Release (PDF)

> Abivax posted top-line data from a phase 2a trial of its HIV candidate ABX464. Statement

Suggested Articles

What a difference a day makes in biotech.

A report out this week by PwC thinks that biotech could be in for a good year for deals as it sees the momentum from 2019 growing.

A drug developed at Temple restores a mechanism in brain cells that prevents the toxic buildup of the proteins amyloid beta and tau in Alzheimer's.